{"filing":{"accession_number":"0001388658-26-000070","cik":"0001388658","ticker":"IRTC","company_name":"iRhythm Holdings, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-07-31","primary_document":"irtc-20260731.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1388658/000138865826000070/irtc-20260731.htm"},"events":[{"id":25718,"run_id":23341,"accession_number":"0001388658-26-000070","anchor_item_number":"1.01","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.85,"summary":"iRhythm Technologies and Baxter settled patent litigation involving mutual accusations of patent infringement with a $50 million settlement payment and cross-licenses, resolving all outstanding patent disputes and including covenants not to sue for six years.","company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26617,"accession_number":"0001388658-26-000070","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.85,"reasoning":"iRhythm Technologies and Baxter settled patent litigation involving mutual accusations of patent infringement with a $50 million settlement payment and cross-licenses. The settlement resolves all outstanding patent litigation and includes covenants not to sue for six years. The $50 million payment and resolution of multi-party patent disputes affecting the company's cardiac monitoring technology constitute a material litigation settlement that would affect investor assessment of the registrant's legal and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:25:10.639386+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":25719,"run_id":23341,"accession_number":"0001388658-26-000070","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"iRhythm issued its Q2 2026 earnings release disclosing revenue of $224.2 million (20.1% YoY growth), gross margin of 72.8%, net loss of $0.4 million, and adjusted EBITDA of $43.3 million, while raising full-year 2026 revenue guidance to $880–$890 million and adjusted EBITDA margin guidance to 13.0–14.0%.","company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26618,"accession_number":"0001388658-26-000070","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"iRhythm issued a press release on August 6, 2026 disclosing its financial results for the second quarter ended June 30, 2026. The disclosure includes revenue of $224.2 million (20.1% YoY growth), gross margin of 72.8%, net loss of $0.4 million (a $13.8 million improvement), and adjusted EBITDA of $43.3 million. The company also raised its full-year 2026 revenue guidance to $880–$890 million and adjusted EBITDA margin guidance to 13.0–14.0%. This is a standard quarterly earnings release furnished as Exhibit 99.1, meeting the definition of earnings_release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:25:10.639386+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":25720,"run_id":23341,"accession_number":"0001388658-26-000070","anchor_item_number":"7.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"iRhythm entered into a definitive agreement to acquire Vital Connect, Inc. for approximately $287.5 million, a material acquisition that expands the company's addressable market in cardiac monitoring technology.","company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26619,"accession_number":"0001388658-26-000070","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure announces iRhythm's entry into a definitive agreement to acquire Vital Connect, Inc. for approximately $287.5 million. This is a material acquisition that expands iRhythm's addressable market and represents a significant strategic transaction. Although disclosed under Item 7.01 (Regulation FD Disclosure) rather than the typical Item 1.01 (Business Combinations), the substance is clearly a material M\u0026A activity that would affect a reasonable investor's assessment of the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:25:10.639386+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26617,"accession_number":"0001388658-26-000070","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.85,"reasoning":"iRhythm Technologies and Baxter settled patent litigation involving mutual accusations of patent infringement with a $50 million settlement payment and cross-licenses. The settlement resolves all outstanding patent litigation and includes covenants not to sue for six years. The $50 million payment and resolution of multi-party patent disputes affecting the company's cardiac monitoring technology constitute a material litigation settlement that would affect investor assessment of the registrant's legal and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:25:10.639386+00:00","company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","filing_date":"2026-08-06"},{"id":26618,"accession_number":"0001388658-26-000070","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"iRhythm issued a press release on August 6, 2026 disclosing its financial results for the second quarter ended June 30, 2026. The disclosure includes revenue of $224.2 million (20.1% YoY growth), gross margin of 72.8%, net loss of $0.4 million (a $13.8 million improvement), and adjusted EBITDA of $43.3 million. The company also raised its full-year 2026 revenue guidance to $880–$890 million and adjusted EBITDA margin guidance to 13.0–14.0%. This is a standard quarterly earnings release furnished as Exhibit 99.1, meeting the definition of earnings_release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:25:10.639386+00:00","company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","filing_date":"2026-08-06"},{"id":26619,"accession_number":"0001388658-26-000070","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure announces iRhythm's entry into a definitive agreement to acquire Vital Connect, Inc. for approximately $287.5 million. This is a material acquisition that expands iRhythm's addressable market and represents a significant strategic transaction. Although disclosed under Item 7.01 (Regulation FD Disclosure) rather than the typical Item 1.01 (Business Combinations), the substance is clearly a material M\u0026A activity that would affect a reasonable investor's assessment of the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:25:10.639386+00:00","company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","filing_date":"2026-08-06"}]}